KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Nov 13

PMID 34768355

Citations 6

Authors

Yohei Sekino

Quoc Thang Pham

Kohei Kobatake

Hiroyuki Kitano

Kenichiro Ikeda

Keisuke Goto

Tetsutaro Hayashi

Hikaru Nakahara

Kazuhiro Sentani

Naohide Oue

Wataru Yasui

Jun Teishima

Nobuyuki Hinata

Affiliations

Soon will be listed here.

Abstract

Kinesin family member C1 (), a minus end-directed motor protein, is reported to play an essential role in cancer. This study aimed to analyze expression and examine involvement in cisplatin resistance in bladder cancer (BC). Immunohistochemistry showed that 37 of 78 (47.4%) BC cases were positive for . -positive cases were associated with high T stage and lymph node metastasis. Kaplan-Meier analysis showed that -positive cases were associated with poor prognosis, consistent with the results from public databases. Molecular classification in several public databases indicated that expression was increased in basal type BC. Immunohistochemistry showed that -positive cases were associated with basal markers 34βE12, CK5 and CD44. expression was increased in altered compared to that in wild-type . Immunohistochemistry showed that -positive cases were associated with p53-positive cases. P53 knockout by CRISPR-Cas9 induced expression in BC cell lines. Knockdown of by siRNA increased the sensitivity to cisplatin in BC cells. Kaplan-Meier analysis indicated that prognosis was poor among -positive BC patients treated with cisplatin-based chemotherapy. Immunohistochemistry showed that -positive cases were associated with PD-L1-positive cases. High expression was associated with a favorable prognosis in patients treated with atezolizumab from the IMvigor 210 study. These results suggest that might be a promising biomarker and therapeutic target in BC.

Citing Articles

Cell cycle-dependent centrosome clustering precedes proplatelet formation.

Becker I, Wilkie A, Nikols E, Carminita E, Roweth H, Tilburg J Sci Adv. 2024; 10(25):eadl6153.

PMID: 38896608 PMC: 11186502. DOI: 10.1126/sciadv.adl6153.

A comprehensive analysis of the prognostic and immunotherapeutic characteristics of KIFC1 in pan-cancer and its role in the malignant phenotype of pancreatic cancer.

Zhang S, Qin O, Xu H, Wu S, Huang W, Song H Aging (Albany NY). 2023; 15(24):14845-14863.

PMID: 38112634 PMC: 10781448. DOI: 10.18632/aging.205311.

KIFC1 promotes proliferation and pseudo-bipolar division of ESCC through the transportation of Aurora B kinase.

Du B, Wei L, Wang J, Li Y, Huo J, Wang J Aging (Albany NY). 2023; 15(21):12633-12650.

PMID: 37955677 PMC: 10683620. DOI: 10.18632/aging.205203.

LncRNA landscape and associated ceRNA network in placental villus of unexplained recurrent spontaneous abortion.

Tang M, Li Q, Wan S, Chen Q, Feng S, You J Reprod Biol Endocrinol. 2023; 21(1):57.

PMID: 37340405 PMC: 10280933. DOI: 10.1186/s12958-023-01107-4.

The Roles of KIFC1 in the Development of Osteosarcoma: Characterization of Potential Therapeutic Targets.

Liang L, Li G Comput Math Methods Med. 2022; 2022:5039134.

PMID: 35479190 PMC: 9038405. DOI: 10.1155/2022/5039134.

References

Tan T, Rouanne M, Tan K, Huang R, Thiery J . Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. 2018; 75(3):423-432. DOI: 10.1016/j.eururo.2018.08.027. View

Sekino Y, Han X, Babasaki T, Miyamoto S, Kitano H, Kobayashi G . TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma. Oncology. 2020; 98(10):689-698. DOI: 10.1159/000506775. View

Hodgson A, Liu S, Vesprini D, Xu B, Downes M . Basal-subtype bladder tumours show a 'hot' immunophenotype. Histopathology. 2018; 73(5):748-757. DOI: 10.1111/his.13696. View

Muller P, Vousden K . p53 mutations in cancer. Nat Cell Biol. 2012; 15(1):2-8. DOI: 10.1038/ncb2641. View

Kim W, Kim E, Kim S, Kim Y, Ha Y, Jeong P . Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010; 9:3. PMC: 2821358. DOI: 10.1186/1476-4598-9-3. View

Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog S . Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020; 11(1):4858. PMC: 7519650. DOI: 10.1038/s41467-020-18640-0. View

Rebouissou S, Bernard-Pierrot I, De Reynies A, Lepage M, Krucker C, Chapeaublanc E . EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014; 6(244):244ra91. DOI: 10.1126/scitranslmed.3008970. View

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi B . Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 2016; 30(1):27-42. DOI: 10.1016/j.ccell.2016.05.004. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

10.

Xiao K, Teng K, Ye Y, Tan L, Chen M, Liang H . Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt/GSK3β signaling. Cancer Sci. 2019; 110(9):2822-2833. PMC: 6726677. DOI: 10.1111/cas.14126. View

11.

Ganem N, Godinho S, Pellman D . A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009; 460(7252):278-82. PMC: 2743290. DOI: 10.1038/nature08136. View

12.

Ogihara K, Kikuchi E, Okazaki S, Hagiwara M, Takeda T, Matsumoto K . Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer Sci. 2019; 110(4):1431-1441. PMC: 6447829. DOI: 10.1111/cas.13960. View

13.

Robertson A, Groeneveld C, Jordan B, Lin X, McLaughlin K, Das A . Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. 2020; 78(4):533-537. DOI: 10.1016/j.eururo.2020.06.048. View

14.

Davis A, Patel V . The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7(1):278. PMC: 6815032. DOI: 10.1186/s40425-019-0768-9. View

15.

Yamamoto Y, Matsuyama H, Furuya T, Oga A, Yoshihiro S, Okuda M . Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res. 2004; 10(19):6449-55. DOI: 10.1158/1078-0432.CCR-04-0773. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Kamoun A, De Reynies A, Allory Y, Sjodahl G, Robertson A, Seiler R . A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2019; 77(4):420-433. PMC: 7690647. DOI: 10.1016/j.eururo.2019.09.006. View

18.

Tchounwou P, Dasari S, Noubissi F, Ray P, Kumar S . Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol. 2021; 13:303-328. PMC: 7987268. DOI: 10.2147/JEP.S267383. View

19.

Sekino Y, Han X, Babasaki T, Miyamoto S, Kobatake K, Kitano H . TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer. Urol Oncol. 2021; 39(6):368.e1-368.e9. DOI: 10.1016/j.urolonc.2021.03.001. View

20.

Choi W, Porten S, Kim S, Willis D, Plimack E, Hoffman-Censits J . Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25(2):152-65. PMC: 4011497. DOI: 10.1016/j.ccr.2014.01.009. View